Navigation Links
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Date:5/21/2008

th moderate to severe Crohn's disease to study the safety and efficacy of HUMIRA in maintaining clinical remission up to 56 weeks. After week four, 778 patients were randomized to placebo, HUMIRA 40 mg every other week (EOW) or 40 mg weekly (EW) in blinded fashion. At or after week 12, patients with flares or non-responders could receive open-label 40 mg EOW and 40 mg EW for continued flare or nonresponse.

The co-primary endpoints evaluated the maintenance of clinical remission at weeks 26 and 56 for each HUMIRA group compared to those on placebo. A significantly greater percentage of patients treated with HUMIRA maintained clinical remission at one year compared to placebo.

About the GAIN Trial

In the GAIN (Gauging Adalimumab effectiveness in Infliximab Nonresponders) study, a four-week induction trial of 325 patients who lost response or were intolerant to infliximab, three times as many patients taking HUMIRA achieved clinical remission at week four versus placebo (21 percent versus 7 percent, respectively).

"HUMIRA's ability to effectively treat the chronic symptoms of Crohn's disease makes it an important option for gastroenterologists and patients looking for improved disease management," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott.

HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. HUMIRA is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

The recommended HUMIRA dose regimen for adult patients with Crohn's disease is 160 mg initially at Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later (Day 15).
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... California , September 1, 2015 ... is segmented on the basis of sectors, products ... chronic diseases globally coupled with the increasing demand ... diseases are expected to propel the growth for ... manage biological information efficiently is known as bioinformatics. ...
(Date:9/1/2015)... Aug. 31, 2015 Research and Markets ( ... "Regulatory Affairs for Support Staff (London, UK - September ... This two day course provides an introduction to ... and has been designed specifically for those working in ... gain an overview of EU regulatory procedures required to ...
(Date:9/1/2015)... 2015 - The ... egistry data presented at ESC Congress ... the evolution of manag ing AF in ... -   The first-ever two-year outcomes from the Global Anticoagulant ... expose that all-cause death was the most frequent major event in more than ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
... U.S. Food and Drug Administration today approved Ferriprox (deferiprone) ... transfusions in patients with thalassemia, a genetic blood disorder ... prior chelation therapy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... iron in the body from the frequent blood transfusions ...
... SAN RAMON, Calif., Oct. 14, 2011 Armanino ... successful company-wide Microsoft Dynamics AX implementation and the ... MES (Manufacturing Engineering System) to streamline the production ... equipment.  Microsoft Dynamics AX is a comprehensive business ...
Cached Medicine Technology:FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 2FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 3Armanino Consulting Completes Integration of Microsoft Dynamics AX and Camstar MES for dpiX 2Armanino Consulting Completes Integration of Microsoft Dynamics AX and Camstar MES for dpiX 3
(Date:9/1/2015)... ... , ... Earth Brands, ( http://www.earthbrands.com ) a comfort-meets-fashion women’s ... buys an Earth Brand shoe will be given an opportunity to plant a ... a nonprofit dedicated to planting more trees. Earth Brands products represent contemporary designs ...
(Date:9/1/2015)... ... September 01, 2015 , ... ProRehab Physical Therapy , ... partnership with Apex Physical Therapy (Apex) is official as of August ... compassionate, and empathetic care to local residents from their combined eight locations throughout ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... not managed, stress created from everyday life changes can lead to very serious, ... provide support for coping with stress. Herbal supplement manufacturer MediHerb has ...
(Date:9/1/2015)... ... 01, 2015 , ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive ... Camp Compass® has taken place at Kingsborough Community College in Brooklyn in each of ... work for Calvary, and two junior counselors who were campers themselves just a few ...
(Date:9/1/2015)... ... 2015 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) has ... LATINA Style 50 Report that recognizes companies that provide the best career opportunities for ... climbs from number 24 to 21 of the 50 Best Companies for Latinas. The ...
Breaking Medicine News(10 mins):Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3
... with God, affects medical choices, study finds , FRIDAY, Dec. 18 ... cancer could be just as important as taking care of their ... what was important to them at the end of their lives, ... being at peace with God, the study found. , "Medicine ...
... ... the nostrils help deliver scent molecules into the nose to the olfactory bulb, where ... From there, they are forwarded to areas of the central nervous system that mediate ... ...
... ... used across a range of enterprise activities , ... Washington, D.C. (PRWEB) December 18, 2009 -- Applied Predictive Technologies ... in the world, has signed an agreement to license APT,s Test & Learn Management System. ...
... Make your ... certificates and his own name-brand prescription-strength line of skincare products for Christmas. ... Denver, CO (PRWEB) December 17, ... your shopping done! Online gift certificates are now available at www.ravalmd.com and ...
... , , NEW YORK, Dec. 17 The Hebrew University ... Tropical Diseases has received a $5 million grant from the ... The project will be led by Professor Alon Warburg, ... and will include experts from Hebrew University,s Robert H. Smith ...
... , ... , EDF calls for dirty heating oil phase out by 2020 ... of the city,s heating oil soot pollution is created by burning the dirtiest ... City, according to a new report released today by ...
Cached Medicine News:Health News:Spiritual Needs Rank High as Death From Cancer Nears 2Health News:Spiritual Needs Rank High as Death From Cancer Nears 3Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 2Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 3Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 4Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 5Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 6Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 7Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 8Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 9Health News:Banfield, The Pet Hospital Signs Agreement to License APT's Test & Learn Management System 2Health News:Banfield, The Pet Hospital Signs Agreement to License APT's Test & Learn Management System 3Health News:Streamline Your Holiday Shopping With Online Savings At Ravalmd.com 2Health News:Bill & Melinda Gates Foundation Grants $5 Million For Infectious Disease Research At The Hebrew University Of Jerusalem 2Health News:Bill & Melinda Gates Foundation Grants $5 Million For Infectious Disease Research At The Hebrew University Of Jerusalem 3Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 2Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 3Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 4
... the newest and most advanced automated immunoassay ... AIA-1800 launches with a full menu of ... reproductive, cardiac, and anemia assays. ,The AIA-1800 ... primary tube sampling, auto dilution, auto pretreatment, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
Medicine Products: